| Record Information |
| Version |
3.5 |
| Creation Date |
2005-11-16 08:48:42 -0700 |
| Update Date |
2013-02-08 17:08:03 -0700 |
| HMDB ID |
HMDB00191 |
| Secondary Accession Numbers |
None |
| Metabolite Identification |
| Common Name |
L-Aspartic acid |
| Description |
Aspartic acid (Asp, D), also known as aspartate, the name of its anion, is one of the 20 natural proteinogenic amino acids which are the building blocks of proteins. As its name indicates, aspartic acid is the carboxylic acid analog of asparagine. As a neurotransmitter, aspartic acid may provide resistance to fatigue and thus lead to endurance, although the evidence to support this idea is not strong. (http://en.wikipedia.org/wiki/Aspartic_acid) Aspartic acid is a nonessential amino acid which is made from glutamic acid by enzymes using vitamin B6. The amino acid has important roles in the urea cycle and DNA metabolism. Aspartic acid is a major excitatory neurotransmitter, which is sometimes found to be increased in epileptic and stroke patients. It is decreased in depressed patients and in patients with brain atrophy. Aspartic acid supplements are being evaluated. Five grams can raise blood levels. Magnesium and zinc may be natural inhibitors of some of the actions of aspartic acid. Aspartic acid, with the amino acid phenylalanine, is a part of a new natural sweetener, aspartame. This sweetener is an advance in artificial sweeteners, and is probably safe in normal doses to all except phenylketonurics. The jury is still out on the long term effects it has on many brain neurohormones. Aspartic acid may be a significant immunostimulant of the thymus and can protect against some of the damaging effects of radiation. Many claims have been made for the special value of administering aspartic acid in the form of potassium and magnesium salts. Since aspartic acid is relatively nontoxic, studies are now in progress to elucidate its pharmacological and therapeutic roles. (http://www.dcnutrition.com/AminoAcids). |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- Asp
- (+)-Aspartate
- (+)-Aspartic acid
- (2S)-Aspartate
- (2S)-Aspartic acid
- (L)-Aspartate
- (L)-Aspartic acid
- (R)-2-aminosuccinate
- (S)-(+)-Aspartate
- (S)-(+)-Aspartic acid
- (S)-2-aminosuccinate
- (S)-2-aminosuccinic acid
- (S)-amino-Butanedioate
- (S)-amino-Butanedioic acid
- (S)-Aminobutanedioate
- (S)-Aminobutanedioic acid
- (S)-Aspartate
- (S)-Aspartic acid
- 2-Amino-3-methylsuccinate
- 2-Amino-3-methylsuccinic acid
- 2-Aminosuccinate
- 2-Aminosuccinic acid
- alpha-Aminosuccinate
- alpha-Aminosuccinic acid
- Aminosuccinate
- Asparagate
- Asparagic acid
- Asparaginate
- Asparaginic acid
- Asparatate
- Aspartate
- H-Asp-OH
- L-(+)-Aspartate
- L-(+)-Aspartic acid
- L-Aminosuccinate
- L-Aminosuccinic acid
- L-Asparagate
- L-Asparagic acid
- L-Asparaginate
- L-Asparaginic acid
- L-Aspartate
|
| Chemical Formula |
C4H7NO4 |
| Average Molecular Weight |
133.1027 |
| Monoisotopic Molecular Weight |
133.037507717 |
| IUPAC Name |
(2S)-2-aminobutanedioic acid |
| Traditional IUPAC Name |
L-aspartic acid |
| CAS Registry Number |
56-84-8 |
| SMILES |
N[C@@H](CC(O)=O)C(O)=O |
| InChI Identifier |
InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1 |
| InChI Key |
CKLJMWTZIZZHCS-REOHCLBHSA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Amino Acids, Peptides, and Analogues |
| Class |
Amino Acids and Derivatives |
| Sub Class |
Alpha Amino Acids and Derivatives |
| Other Descriptors |
- Aliphatic Acyclic Compounds
- Amino acids(KEGG)
- Common amino acids(KEGG)
- L-alpha-amino acid(ChEBI)
- aspartic acid(ChEBI)
|
| Substituents |
- 1,3 Aminoalcohol
- Carboxylic Acid
- Dicarboxylic Acid Derivative
- Primary Aliphatic Amine (Alkylamine)
- Succinic Acid
|
| Direct Parent |
Alpha Amino Acids and Derivatives |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
- Component of Alanine and aspartate metabolism
- Component of Arginine and proline metabolism
- Component of Cysteine metabolism
- Component of Glutamate metabolism
- Component of Histidine metabolism
- Component of Nitrogen metabolism
- Component of Novobiocin biosynthesis
- Component of Phenylalanine metabolism
- Component of Phenylalanine, tyrosine and tryptophan biosynthesis
- Component of Purine metabolism
- Component of Tyrosine metabolism
- Essential amino acid
- Non-essential amino acid
|
| Application |
Not Available |
| Cellular locations |
- Cytoplasm
- Extracellular
- Mitochondria
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
270 °C |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
5.39 mg/mL |
YALKOWSKY,SH & DANNENFELSER,RM (1992) |
| LogP |
-3.89 |
CHMELIK,J ET AL. (1991) |
|
| Predicted Properties |
|
| Spectra |
|
| Gas-MS Spectrum |
| 1H NMR Spectrum |
| 13C NMR Spectrum |
| MS/MS Spectrum Quattro_QQQ 10 |
| MS/MS Spectrum Quattro_QQQ 25 |
| MS/MS Spectrum Quattro_QQQ 40 |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| MS/MS Spectrum LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) |
| [1H,1H] 2D NMR Spectrum |
| [1H,13C] 2D NMR Spectrum |
|
| Biological Properties |
| Cellular Locations |
- Cytoplasm
- Extracellular
- Mitochondria
|
| Biofluid Locations |
- Blood
- Cerebrospinal Fluid (CSF)
- Saliva
- Urine
|
| Tissue Location |
|
| Pathways |
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
21.0 +/- 5.0 uM |
Adult (>18 years old) |
Male |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
20.0 +/- 5.0 uM |
Adult (>18 years old) |
Female |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
20.9 +/- 6.1 uM |
Adult (>18 years old) |
Not Specified |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.30 (0.0-4.6) uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.8 +/- 1.2 uM |
Adult (>18 years old) |
Male |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
1.8 +/- 0.2 uM |
Adult (>18 years old) |
Female |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.6 +/- 0.3 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2.19 +/- 2.63 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.23 +/- 0.18 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Saliva |
Detected and Quantified |
|
>10 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
1.36 +/- 1.06 umol/mmol creatinine |
Infant (0-1 year old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
0.32 (0.30-0.45) umol/mmol creatinine |
Newborn (0-30 days old) |
Both |
Normal |
Not Available |
| Urine |
Detected and not Quantified |
|
Not Applicable |
Adult (>18 years old) |
Both |
Normal |
Urine compound detected by GC-MS
|
| Urine |
Detected and Quantified |
|
10.9 (3.5-21.8) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
urine by NMR
|
| Urine |
Detected and Quantified |
|
5.2 +/- 6.15 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
10.9 (1.9-26.8) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
by LC-MS/MS (Biocrates kit)
|
| Urine |
Detected and Quantified |
|
0.5 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
4.638 (1.711-7.566) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
|
| Abnormal Concentrations |
|
| Blood |
Detected and Quantified |
|
36.0 +/- 9.0 uM |
Adult (>18 years old) |
Both |
Cirrhosis |
Not Available |
| Blood |
Detected and Quantified |
|
3.9 (3.7-4.1) uM |
Adult (>18 years old) |
Both |
Epilepsy |
Refractory localization-related epilepsy (RLE)
|
| Blood |
Detected and Quantified |
|
11.8 (10.9-12.7) uM |
Adult (>18 years old) |
Both |
Epilepsy |
Acute seizures
|
| Blood |
Detected and Quantified |
|
12.67 +/- 2.86 uM |
Elderly (>65 years old) |
Both |
Alzheimer's disease |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.233 +/- 0.081 uM |
Adult (>18 years old) |
Not Specified |
Growth hormone deficiency |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
0.24 +/- 0.10 uM |
Adult (>18 years old) |
Both |
Schizophrenia |
Not Available |
|
| Associated Disorders and Diseases |
| Disease References |
| Epilepsy |
- Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P: Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 2004 Jan;29(1):319-24.
Pubmed: 14992292
|
| Growth hormone deficiency |
- Burman P, Hetta J, Wide L, Mansson JE, Ekman R, Karlsson FA: Growth hormone treatment affects brain neurotransmitters and thyroxine [see comment] Clin Endocrinol (Oxf). 1996 Mar;44(3):319-24.
Pubmed: 8729530
|
| Cirrhosis |
- Cynober LA: Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition. 2002 Sep;18(9):761-6.
Pubmed: 12297216
|
| Alzheimer's disease |
- Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG: Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids. 2007 Feb;32(2):213-24. Epub 2006 Oct 10.
Pubmed: 17031479
|
| Schizophrenia |
- Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F: gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995 Dec;65(6):2652-62.
Pubmed: 7595563
|
|
| Associated OMIM IDs |
|
| External Links |
| DrugBank ID |
DB00128  |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB012567 |
| KNApSAcK ID |
C00001342  |
| Chemspider ID |
5745  |
| KEGG Compound ID |
C00049  |
| BioCyc ID |
L-ASPARTATE  |
| BiGG ID |
33663  |
| Wikipedia Link |
Asp  |
| NuGOwiki Link |
HMDB00191  |
| Metagene Link |
HMDB00191  |
| METLIN ID |
5206  |
| PubChem Compound |
5960  |
| PDB ID |
ASP  |
| ChEBI ID |
17053  |
| References |
| Synthesis Reference |
Pamfil, Maria; Lupescu, Irina; Savoiu, Valeria Gabriela. L-aspartic acid production from fumarate using Escherichia coli whole cells. Rom. (2005), 3pp. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Fujii N: D-amino acid in elderly tissues. Biol Pharm Bull. 2005 Sep;28(9):1585-9.
Pubmed: 16141520
- Cynober LA: Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition. 2002 Sep;18(9):761-6.
Pubmed: 12297216
- Grdzelishvili VZ, Smallwood S, Tower D, Hall RL, Hunt DM, Moyer SA: A single amino acid change in the L-polymerase protein of vesicular stomatitis virus completely abolishes viral mRNA cap methylation. J Virol. 2005 Jun;79(12):7327-37.
Pubmed: 15919887
- Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P: Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 2004 Jan;29(1):319-24.
Pubmed: 14992292
- Lockridge O: Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther. 1990;47(1):35-60.
Pubmed: 2195556
- Franklin RB, Zou J, Yu Z, Costello LC: EAAC1 is expressed in rat and human prostate epithelial cells; functions as a high-affinity L-aspartate transporter; and is regulated by prolactin and testosterone. BMC Biochem. 2006 Mar 27;7:10.
Pubmed: 16566829
- Advani SJ, Hagglund R, Weichselbaum RR, Roizman B: Posttranslational processing of infected cell proteins 0 and 4 of herpes simplex virus 1 is sequential and reflects the subcellular compartment in which the proteins localize. J Virol. 2001 Sep;75(17):7904-12.
Pubmed: 11483735
- Wang M, Meng Z, Fu J: Synthesis and biodistribution of six novel 99mTc complexes of 2-hydroxybenzaldehyde-amino acid Schiff bases. Appl Radiat Isot. 2006 Feb;64(2):235-40.
Pubmed: 16309915
- Fisher G, Lopez S, Peterson K, Goff T, Philip I, Gaviria R, Lorenzo N, Tsesarskaia M: Is there a correlation between age and D: -aspartic acid in human knee cartilage? Amino Acids. 2006 Jun 1;.
Pubmed: 16738792
- Baslow MH: Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation. J Mol Neurosci. 2003;21(3):185-90.
Pubmed: 14645985
- Shao B, Belaaouaj A, Verlinde CL, Fu X, Heinecke JW: Methionine sulfoxide and proteolytic cleavage contribute to the inactivation of cathepsin G by hypochlorous acid: an oxidative mechanism for regulation of serine proteinases by myeloperoxidase. J Biol Chem. 2005 Aug 12;280(32):29311-21. Epub 2005 Jun 20.
Pubmed: 15967795
- Silwood CJ, Lynch E, Claxson AW, Grootveld MC: 1H and (13)C NMR spectroscopic analysis of human saliva. J Dent Res. 2002 Jun;81(6):422-7.
Pubmed: 12097436
- Rose CH, Thigpen BD, Bofill JA, Cushman J, May WL, Martin JN Jr: Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. Obstet Gynecol. 2004 Nov;104(5 Pt 1):1011-4.
Pubmed: 15516393
- Chiara F, Goumans MJ, Forsberg H, Ahgren A, Rasola A, Aspenstrom P, Wernstedt C, Hellberg C, Heldin CH, Heuchel R: A gain of function mutation in the activation loop of platelet-derived growth factor beta-receptor deregulates its kinase activity. J Biol Chem. 2004 Oct 8;279(41):42516-27. Epub 2004 Jul 28.
Pubmed: 15284236
- Bhende PM, Seaman WT, Delecluse HJ, Kenney SC: BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J Virol. 2005 Jun;79(12):7338-48.
Pubmed: 15919888
- Nicholson JK, O'Flynn MP, Sadler PJ, Macleod AF, Juul SM, Sonksen PH: Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects. Biochem J. 1984 Jan 15;217(2):365-75.
Pubmed: 6696735
- Engelborghs S, Marescau B, De Deyn PP: Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. Neurochem Res. 2003 Aug;28(8):1145-50.
Pubmed: 12834252
- Burman P, Hetta J, Wide L, Mansson JE, Ekman R, Karlsson FA: Growth hormone treatment affects brain neurotransmitters and thyroxine [see comment] Clin Endocrinol (Oxf). 1996 Mar;44(3):319-24.
Pubmed: 8729530
- Butterworth RF: Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis. 2002 Dec;17(4):221-7.
Pubmed: 12602499
- Hagenfeldt L, Bjerkenstedt L, Edman G, Sedvall G, Wiesel FA: Amino acids in plasma and CSF and monoamine metabolites in CSF: interrelationship in healthy subjects. J Neurochem. 1984 Mar;42(3):833-7.
Pubmed: 6198473
- Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4.
Pubmed: 19212411
|
| Enzymes |
|
|
|
|
| Name: |
Ribonuclease pancreatic
|
| Reactions: |
- Endonucleolytic cleavage to nucleoside 3'-phosphates and 3'-phosphooligonucleotides ending in Cp or Up with 2',3'-cyclic phosphate intermediates REFERENCE 1 AUTHORS Anfinsen, C.B. and White, F.H., Jr. TITLE The ribonucleases: occurrence, structure, and properties. JOURNAL In: Boyer, P.D., Lardy, H. and Myrback, K. (Eds.), The Enzymes, 2nd ed., vol. 5, Academic Press, New York, 1961, p. 95-122. REFERENCE 2 [PMID:14247667] AUTHORS BEARD JR, RAZZELL WE. TITLE PURIFICATION OF ALKALINE RIBONUCLEASE II FROM MITOCHONDRIAL AND SOLUBLE FRACTIONS OF LIVER. JOURNAL J. Biol. Chem. 239 (1964) 4186-93.
|
| Gene Name: |
RNASE1 |
| Uniprot ID: |
P07998  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Aminoacylase-1
|
| Reactions: |
- an N-acyl-L-amino acid + H2O = a carboxylate + an L-amino acid [RN:R01263]
|
| Gene Name: |
ACY1 |
| Uniprot ID: |
Q03154  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Aspartoacylase
|
| Reactions: |
- N-acyl-L-aspartate + H2O = a carboxylate + L-aspartate [RN:R00546]
|
| Gene Name: |
ASPA |
| Uniprot ID: |
P45381  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
| Name: |
Asparagine synthetase [glutamine-hydrolyzing]
|
| Reactions: |
- (1) ATP + L-aspartate + L-glutamine + H2O = AMP + diphosphate + L-asparagine + L-glutamate [RN:R00578]
- (2) (1a) L-glutamine + H2O = L-glutamate + NH3 [RN:R00256]
- (3) (1b) ATP + L-aspartate + NH3 = AMP + diphosphate + L-asparagine [RN:R00483]
|
| Gene Name: |
ASNS |
| Uniprot ID: |
P08243  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
| Name: |
Argininosuccinate synthase
|
| Reactions: |
- ATP + L-citrulline + L-aspartate = AMP + diphosphate + 2-(Nomega-L-arginino)succinate [RN:R01954]
|
| Gene Name: |
ASS1 |
| Uniprot ID: |
P00966  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
|
|
|
|
|
|
|
|
| Name: |
Multifunctional protein ADE2
|
| Reactions: |
- ATP + 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate + L-aspartate = ADP + phosphate + (S)-2-[5-amino-1-(5-phospho-D-ribosyl)imidazole-4- carboxamido]succinate [RN:R04591]
|
| Gene Name: |
PAICS |
| Uniprot ID: |
P22234  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
| Name: |
Lysozyme C
|
| Reactions: |
- Hydrolysis of (1->4)-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in a peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrins
|
| Gene Name: |
LYZ |
| Uniprot ID: |
P61626  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
|
|
|
|
| Name: |
CAD protein
|
| Reactions: |
- (1) 2 ATP + L-glutamine + HCO3- + H2O = 2 ADP + phosphate + L-glutamate + carbamoyl phosphate [RN:R00575]
- (2) L-glutamine + H2O = L-glutamate + NH3 [RN:R00256]
- (3) 2 ATP + HCO3- = 2 ADP + phosphate + carbamoyl phosphate [RN:R07641]
|
| Gene Name: |
CAD |
| Uniprot ID: |
P27708  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
L-asparaginase
|
| Reactions: |
- L-asparagine + H2O = L-aspartate + NH3 [RN:R00485]
|
| Gene Name: |
ASRGL1 |
| Uniprot ID: |
Q7L266  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
| Name: |
Argininosuccinate synthase
|
| Reactions: |
- ATP + L-citrulline + L-aspartate = AMP + diphosphate + 2-(Nomega-L-arginino)succinate [RN:R01954]
|
| Gene Name: |
ASS1 |
| Uniprot ID: |
Q5T6L4  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|